An Overview of EuroQol EQ-5D: Quality-of-Life Assessment

EuroQol EQ-5D questionnaires turn how patients feel into scores that regulators and payers trust. Pharma teams rely on them to show that a medicine improves quality of life, not only survival outcomes. 

Image

What EuroQol EQ-5D Measures and Why it Matters in Clinical Development

EuroQol is an international not-for-profit organisation that develops and maintains standardised measures of health-related quality of life, including the widely used EQ-5D. Its instruments help researchers capture how patients experience their health across areas such as mobility, self-care, daily activities, pain, and mental wellbeing.

Its Foundation sits in Rotterdam, funds research, and supports instrument users. A separate Group brings together 124 researchers from 30 countries. The name nods to European roots, but the work is now global.

For Clinical Development, EuroQol provides a structured way to bring the patient’s perspective into evidence generation, connecting clinical outcomes with health economics, healthcare decisions, and the assessment of treatment value.

The EQ-5D measures health-related quality of life (HRQoL) across five areas: Mobility, self-care, usual activities, pain or discomfort, and anxiety or depression.

A visual analogue scale, the EQ VAS, then records overall health from 0 to 100. Patients finish the form in a few minutes.

The real value lies in the scoring. Each health state carries a value set built from public preferences.

Analysts use those scores to calculate quality-adjusted life years (QALYs), the metric behind most cost-effectiveness work and health technology assessment (HTA) analysis.

For sponsors, this matters at every stage of Clinical Development.

Late-phase trials add the EQ-5D to capture patient benefit beyond clinical endpoints. Payers then read those scores against comparators. A medicine with a modest survival gain can still build a strong value case if it improves daily functioning.

Reach and funding

The figures show how embedded the tools have become:

• More than 14,000 PubMed papers mention EQ-5D, and about 1,800 name it in the title.
• Close to 6,000 new requests to use the instruments arrived in 2024.
• Non-commercial use is free and covers about 90% of registered users.
• For-profit pharma and life sciences companies, around 10% of users, pay licence fees.
• The Foundation allocates roughly five to six million euros each year to research grants.

Industry therefore plays a direct role. Licence income from sponsor trials funds the methods research that later improves the tools sponsors rely on, including patient-centred endpoints.

Image

Patient-Centricity and Health Economic Assessment

The significance of EuroQol extends beyond collecting another patient-reported endpoint. Its major contribution is the connection between patient experience and economic evaluation.

An EQ-5D health state can be converted into an index value using a country- or region-specific value set. These values reflect preferences from the relevant general population. They are anchored around full health and a state equivalent to death, allowing them to be used in QALY calculations.

That link has helped make EQ-5D central to HTA. The instrument is widely used to estimate QALYs, which combine length and quality of life into a single outcome measure.

This creates an important bridge between clinical evidence and access decisions.

A therapy may demonstrate statistically significant efficacy, but decision-makers also need to understand whether the treatment produces a meaningful improvement in patients’ health and how that improvement compares with its costs and alternatives.

View interview How AI Is Opening New Opportunities in Fertility Care for Pharma

How AI Is Opening New Opportunities in Fertility Care for Pharma

"If I had to get great minds in a room, I'd be looking at it from a tech perspective. How can we take all this knowledge, apply it to policies that can be easily distributed?” Clara Toombs, Fertilia AI.

Image

The EQ-5D Family: From Adults to Children

The EuroQol EQ-5D family now spans adults and children, with each version built around the same five dimensions.

Adult HRQoL versions: EQ-5D-3L and EQ-5D-5L

The original EQ-5D-3L offers three response levels per dimension. The EQ-5D-5L keeps the dimensions but adds two levels and sharper wording. That change reduces ceiling effects and detects smaller health gains, according to a development and preliminary testing study.

The five-level version is now the flagship. It exists in 190 languages and drew 89% of adult instrument requests in 2023 and 2024.

Value sets built with the standardised EuroQol Valuation Technology (EQ-VT) protocol cover 41 countries, which is more than what any other preference-weighted instrument offers.

The three-level version has not completely disappeared. Several HTA guidelines still name it, and its long history supports comparisons with legacy datasets. Sponsors with older trial data often have good reasons to keep using it.

UK filings deserve special attention. The National Institute for Health and Care Excellence (NICE) did not recommend the earlier English value set for the EQ-5D-5L. A new UK value set, published in 2026, has changed that. On 27 August 2026, NICE confirmed it will adopt the new value set in place of the 3L version. 

Child HRQoL versions: EQ-5D-Y-3L and EQ-5D-Y-5L

The child HRQoL instruments keep the five dimensions but use age-appropriate language.

Children aged eight to 15 complete them alone. For ages four to seven, an interviewer or proxy version applies. The Y-3L (three dimension tool) dates from 2009, and EuroQol launched the (five dimension tool) Y-5L in September 2024.

As of 2025, the Y-3L has 10 value sets, more than any other paediatric HRQoL instrument. Researchers are building mapping functions so teams can analyse Y-5L data with existing Y-3L value sets. A Y-5L valuation protocol is still in development. 

Measuring HRQoL across the lifespan

EuroQol wants to measure HRQoL from childhood to old age. The five-level child and adult tools share dimensions that can support models that follow patients into adulthood.

Subtle wording differences and separate value sets still create discontinuities at the transition points. Much ongoing research targets those gaps, and measurement in the oldest age groups is emerging as a priority.

Image

New EuroQol Tools Extend What Trials Can Capture

Three new EQ-5D tools carry “experimental” status.

EuroQol shares them selectively with researchers rather than releasing them widely. Wider approval needs enough psychometric evidence, confirmed translatability, and a minimum set of language versions.

Researchers who want to use them can approach EuroQol directly. Evidence from those studies then helps refine the tools before release, so early collaboration gives sponsors a voice in how they develop.

EQ-TIPS for infants and toddlers

EuroQol Toddler and Infant Populations (EQ-TIPS) targets children aged zero to three, where few validated tools exist. A parent or caregiver completes it.

Version 3.0 covers seven dimensions: Movement, eating or drinking, sleep, pain, managing emotions, interacting with others, and play.

Teams in several countries are testing it. Preference weights are planned, though valuing toddler health states may need different methods.

EQ-HWB for health and wellbeing

EuroQol built the EuroQol Health and Wellbeing instrument (EQ-HWB) with NICE to capture outcomes beyond health, including effects on carers and social care users.

The long version has 25 items, while the short EQ-HWB-9 has only nine.

Seven dimensions apply: Activity, relationships, cognition, self-identity, autonomy, feelings, and physical sensations.

Psychometric testing involved 4,830 participants across six countries. A pilot UK value set exists for the short form.

EQ-5D Bolt-on Toolbox

EQ-5D is deliberately concise. Bolt-ons add items for areas such as vision, hearing, sleep, breathing, or cognition.

Many were proposed ad hoc by third parties, and the evidence base is still evolving. EuroQol is therefore building a curated toolbox of bolt-ons with strong psychometric support in specific patient populations.

Sponsors of disease-specific programmes should watch this space. Where core dimensions miss key benefits, a validated and valued bolt-on could capture them. For example, two bolt-on items for chronic skin disease already have established use.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Image

Valuation Methods, Population Data, and Open Challenges

Beyond new instruments, the EuroQol EQ-5D evidence base is evolving in three areas: How health states are valued, how populations are tracked, and which problems remain unsolved. 

Valuation methods

Value sets turn public opinion into scores.

The long-standing method is time trade-off (TTO) where interviewers ask how many years in full health people would swap for a longer life in a poorer health state.

Discrete choice experiments (DCEs) are now maturing as an alternative. Participants pick between pairs of health states, and analysts infer values from those choices.

Early DCEs that added life duration produced variable, lower-than-expected values, especially for child HRQoL.

Researchers then found people value near-term years above distant ones, known as time preference. Allowing for this has changed results materially.

HTA is also becoming more patient-centred. Value sets built from general population preferences may therefore not be enough to support reimbursement applications.

Research on patient preferences, as a group or individually, are gaining priority, and those studies may need different methods.

Stakeholder engagement is growing too, especially for child HRQoL instruments, because valuing children’s health can raise difficult value judgements.

Population health data

EQ-DAPHNIE builds shared infrastructure for population norms, inequality analysis, and instrument comparison.

Data collection began in 2024 in five countries, with 10 more underway. The initiative will release data from 15 countries covering over 70,000 participants.

Open challenges for HRQoL measures

• Cultural comparability: Items may not read or score identically across health, socioeconomic, and cultural groups, which matters for multi-country trials.
• Age transitions: Child and adult instruments differ subtly, which can create gaps in lifetime models.
• Value set obsolescence: Old and new value sets can yield different QALY estimates, and nobody has agreed when an older set becomes obsolete.
• QALY politics: Criticism has grown, and U.S. legislation has prohibited QALY use in decisions across federal programmes.

Even so, any replacement metrics for patient-reported outcomes still need to be measured and valued by HRQoL. Some way of balancing cost against quality and length of life will remain.

Image

How Sponsors Should Use EuroQol EQ-5D

The EuroQol EQ-5D tools have become the common language for patient-reported health in economic evaluation.

The five-level adult version leads but child versions are maturing, and three experimental tools will widen coverage.

Valuation methods and population datasets are evolving just as fast. The QALY debate will continue, yet the need to measure and value quality of life will not disappear.

Therefore, choose instruments before pivotal protocols lock. Align the version with target HTA guidance, register studies with EuroQol, and plan for value set changes. Remember that new value sets may shift QALY estimates against historic comparators.

You can track the experimental tools through EuroQol’s research programme, and you can view Pharmatica’s Insights on new evidence for patient-reported outcomes as they emerge.

At Pharmatica, we keep score of the evidence frameworks that decide how pharmaceutical value is proven and priced. Our Insights connect Clinical Development and regulation and commercialisation dynamics so decision-makers can act with confidence.

Pharmatica: Insight. Connection. Impact.